Bioenvision

Engages in the acquisition, development and marketing of compounds and technologies primarily for the treatment of cancer.

Launch date

1996

Employees

Market cap

Enterprise valuation

€314m (Public information from May 2007)

New York City New York (HQ)

Date	Investors	Amount	Round
Apr 2007	Perseus Aisling Capital	$7.4m	Early VC
May 2007	Genzyme	$345m Valuation: $345m	Acquisition
Total Funding		€6.7m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Bioenvision